Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M

ARDELYX, INC.

2025-FY EPS reported -$0.26 revenue$407,320,000

Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.
Preliminary unaudited U.S. net product sales: XPHOZAH ~$28M Q4, ~$104M FY 2025.
Cash, cash equivalents and short-term investments ~$265M as of Dec 31, 2025, unaudited.
All figures are preliminary and subject to adjustment upon final audited results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.